MedTrace Logo

Long-term Study With Trazodone Once-a-Day

NCT04295941 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 200

Last updated 2022-09-21

No results posted yet for this study

Summary

The aim of the present observational study is to assess the clinical response, functional impairment and quality of life in outpatients with Major Depressive Disorder who demonstrated an initial positive response to the acute treatment with Trazodone once-a-day monotherapy, for up to 24 weeks.

Conditions

Interventions

DRUG

TraZODone Hydrochloride 300 MG

Oral administration of Trazodone once-a-day.

Sponsors & Collaborators

  • Aziende Chimiche Riunite Angelini Francesco S.p.A

    lead INDUSTRY

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-06-23
Primary Completion
2021-11-16
Completion
2021-11-16

Countries

  • Bulgaria

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04295941 on ClinicalTrials.gov